MCAM and neoplasm: Notably, a study that developed a tumor-specific antibody against CD146, which recognizes CD146 expressed in cancer cells but not in pericytes, indicated the different structural features of tumor-derived CD146 from those of physiological CD146 51, implying the possibility of specifically targeting tumor CD146.